Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Faron Pharmaceuticals Oy    FARN   FI4000153309

FARON PHARMACEUTICALS OY (FARN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/15/2018 06/18/2018 06/19/2018 06/20/2018 06/21/2018 Date
66(c) 61(c) 55(c) 74(c) 68.1999 Last
1 047 509 424 178 946 010 3 838 223 1 278 156 Volume
-13.16% -7.58% -9.84% +34.55% -7.84% Change
More quotes
Financials (GBP)
Sales 2018 1,05 M
EBIT 2018 -16,7 M
Net income 2018 -
Finance 2018 0,27 M
Yield 2018 -
Sales 2019 12,4 M
EBIT 2019 -0,71 M
Net income 2019 -
Finance 2019 28,6 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 15,9x
EV / Sales2019 -0,93x
Capitalization 17,0 M
More Financials
Company
Faron Pharmaceuticals Oy engages in the provision of biopharmaceutical development.The company focuses on novel treatments for medical conditions such as acute organ traumas, cancer immunotherapy and vascular damage.It operates through the Traumakine and Clevegen brands for acute respiratory... 
More about the company
Latest news on FARON PHARMACEUTICALS OY
02/22FARON PHARMACEUTICALS OY : Results of the Placing and Subscription and Issue of ..
AQ
02/20FARON PHARMACEUTICALS OY : Proposed Placing to raise up to GBP15m
AQ
02/06FARON PHARMACEUTICALS OY : establishes second Traumakine manufacturing site as i..
AQ
01/29FARON PHARMACEUTICALS OY : FDA grants Fast Track Designation to Faron for Trauma..
AQ
01/24FDA has approved Faron's Traumakine® IND
GL
2017FARON PHARMACEUTICALS OY : Study update: Traumakine® Phase II/III INFORAAA trial..
AQ
2017FARON PHARMACEUTICALS OY : Recruitment completed in Traumakine INTEREST Trial
GL
2017BIOCENTURY - MANAGEMENT TRACKS : Athenex, Biogen
AQ
2017FARON PHARMACEUTICALS OY : Appointment of Chief Commercial Officer
AQ
2017FARON PHARMACEUTICALS OY : Appointment of Chief Commercial Officer
GL
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/20Faron Pharmaceuticals Oy : Second Price Monitoring Extn  
06/20Faron Pharmaceuticals Oy : Price Monitoring Extension  
05/16Faron Pharmaceuticals Oy : PDMR Shareholding  
05/10Faron Pharmaceuticals Oy : Notice of AGM  
05/08Faron Pharmaceuticals Oy : Top line data from the Phase III INTEREST trial  
More tweets
Qtime:35
Chart FARON PHARMACEUTICALS OY
Duration : Period :
Faron Pharmaceuticals Oy Technical Analysis Chart | FARN | FI4000153309 | 4-Traders
Technical analysis trends FARON PHARMACEUTICALS OY
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Markku Tapani Jalkanen Chief Executive Officer & Executive Director
Frank Murdoch Armstrong Non-Executive Chairman
Mikael Maksimow Vice President-Operations
Yrjö Erik Kristian Wichmann Chief Financial Officer & Executive Director
Matti Karvonen Chief Medical Officer & VP-Drug Development
Sector and Competitors
1st jan.Capitalization (M$)
FARON PHARMACEUTICALS OY-90.75%22
GILEAD SCIENCES-0.98%92 241
VERTEX PHARMACEUTICALS3.10%39 371
REGENERON PHARMACEUTICALS-13.00%34 653
SAREPTA THERAPEUTICS INC176.22%9 432
NEUROCRINE BIOSCIENCES, INC.32.39%9 234